• Santhera, Rutgers Sign Gene Therapy Research Agreements americanpharmaceuticalreview
    May 08, 2020
    Santhera Pharmaceuticals announces the signing of two agreements with Rutgers, The State University of New Jersey as part of its program to advance gene therapy research for the treatment of LAMA2-deficient congenital muscular dystrophy.
PharmaSources Customer Service